Clinical trials - Press Releases

Date	Title	Company
12-Dec-2019	Freeline appoints Julia P Gregory to its Board of Directors	Freeline
12-Dec-2019	Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company	Forendo Pharma
12-Dec-2019	Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors	Transgene
12-Dec-2019	Clevegen downregulates a range of major immuno-oncology (IO) checkpoints in MATINS cancer patients Biomarker analysis could guide future combination therapies with Clevegen	Faron Pharmaceuticals Oy
11-Dec-2019	Dr Samareh Lajaunias, Director at Combioxin Speaking at SMi's 22nd Annual Superbugs & Superdrugs Conference	SMi Group
11-Dec-2019	Invite from Lynne Ensor chair for Pharma Microbiology East Coast Conference, April 2020, Boston	SMi Group
11-Dec-2019	Inceptua Appoints New CEO	Inceptua
10-Dec-2019	Peregrine Ventures Raises $115 Million for its Fourth Fund Bringing Total Managed Funds and Co-Invest Capital to $400 Million	Peregrine
10-Dec-2019	Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion	Sanofi
10-Dec-2019	Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak	Bavarian Nordic
10-Dec-2019	bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition	bluebird bio, Inc
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies	Autolus Therapeutics plc
10-Dec-2019	KITE, A GILEAD COMPANY, ANNOUNCES LONG-TERM DATA FROM ZUMA-1 SHOWING 47% OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS WERE ALIVE THREE YEARS AFTER YESCARTA® (AXICABTAGENE CILOLEUCEL) TREATMENT	Kite, a Gilead Company
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers	Autolus Therapeutics plc
10-Dec-2019	XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen	XBiotech
10-Dec-2019	Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis	Galderma
10-Dec-2019	Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa	Abeona Therapeutics Inc
10-Dec-2019	Acalabrutinib (Calquence) significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia	AstraZeneca
10-Dec-2019	The partnership will provide strategic consulting for life sciences and healthcare companies & providers in Europe	PharmaLex Group
10-Dec-2019	Upperton is Launching an Enabling Technology Screening Protocol	Upperton Pharma Solutions